1. Metabolic Enzyme/Protease
  2. Thrombin

Thrombin

Thrombin is a serine protease that in humans is encoded by the F2 gene. Thrombin is an intriguing coagulation protease demonstrating an array of effects on endothelial cells, vascular smooth muscle cells (VSMC), monocytes, and platelets, all of which are involved in the pathophysiology of atherosclerosis. There is mounting evidence that thrombin acts as a powerful modulator of many processes like regulation of vascular tone, permeability, migration and proliferation of VSMC, recruitment of monocytes into the atherosclerotic lesions, induction of diverse pro-inflammatory markers, and all of these are related to the progression of cardiovascular disease. Recent studies in transgenic mice models indicate that the deletion of the natural thrombin inhibitor heparin cofactor II promotes an accelerated atherogenic state. The combined evidence points to thrombin as a pivotal contributor to vascular pathophysiology. Considering the clinical development of selective anticoagulants including direct thrombin inhibitors.

Thrombin Related Products (14):

Cat. No. Product Name Effect Purity
  • HY-12821
    AEBSF Inhibitor 99.24%
    AEBSF is a water soluble, irreversible serine protease inhibitor; inhibits proteases like chymotrypsin, kallikrein, plasmin, thrombin, and trypsin.
  • HY-10163
    Dabigatran Inhibitor 99.39%
    Dabigatran(BIB-953; BIBR 953ZW) is a reversible and selective, direct thrombin inhibitor (DTI) with Ki value of 4.5 nM.
  • HY-10274
    Dabigatran etexilate Inhibitor 99.37%
    Dabigatran etexilate(BIBR-1048) is the orally active prodrug of dabigatran; Dabigatran is a reversible and selective, direct thrombin inhibitor (DTI) with Ki value of 4.5 nM.
  • HY-10274A
    Dabigatran etexilate mesylate Inhibitor
    Dabigatran etexilate mesylate (BIBR 1048MS) is the orally active prodrug of dabigatran. Dabigatran is a reversible and selective, direct thrombin inhibitor (DTI) with Ki value of 4.5 nM.
  • HY-17378
    Dabigatran ethyl ester Inhibitor 99.26%
    ethyl ester of Dabigatran, which is an emerging oral anticoagulant which is a direct inhibitor of thrombin activity.
  • HY-77521
    Dabigatran ethyl ester hydrochloride Inhibitor 99.36%
    Dabigatran ethyl ester hydrochloride is a potent inhibitor of ribosyldihydronicotinamide dehydrogenase (NQO2) with an IC50 value of 0.8 μM and a thrombin inhibitor.
  • HY-101054
    NQ301 98.74%
    NQ301 is an antithrombotic agent; inhibits collagen-challenged rabbit platelet aggregation with an IC50 of 10 mg/mL.
  • HY-P1000
    Sfllrnpndkyepf Agonist
    SFLLRNPNDKYEPF is a synthetic thrombin receptor agonist peptide.
  • HY-15664
    Bivalirudin Trifluoroacetate Inhibitor 99.67%
    Bivalirudin Trifluoroacetate is a synthetic 20 residue peptide which reversibly inhibits thrombin.
  • HY-B0209
    Metolazone Inhibitor 99.61%
    Metolazone(Zaroxolyn) is primarily used to treat congestive heart failure and high blood pressure.
  • HY-B0375A
    Argatroban monohydrate Inhibitor
    Argatroban monohydrate is a direct, selective thrombin inhibitor.
  • HY-15759A
    Napsagatran hydrate Inhibitor
    Napsagatran hydrate is a novel and specific thrombin inhibitor.
  • HY-B0375
    Argatroban Inhibitor
    Argatroban is a direct, selective thrombin inhibitor.
  • HY-10163AS
    Dabigatran D4 hydrochloride Inhibitor
    Dabigatran D4 hydrochloride is deuterium labeled Dabigatran, which is a reversible and selective, direct thrombin inhibitor (DTI) with Ki value of 4.5 nM.